Cue Biopharma
CUE
38 hedge funds and large institutions have $26.7M invested in Cue Biopharma in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
76% more capital invested
Capital invested by funds: $15.2M → $26.7M (+$11.5M)
6% more funds holding
Funds holding: 36 → 38 (+2)
0.02% more ownership
Funds ownership: 0.53% → 0.56% (+0.02%)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.03M |
| 2 |
BlackRock
New York
|
+$274K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$267K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$240K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$96.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$175K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$124K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$108K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$91K |
| 5 |
State Street
Boston,
Massachusetts
|
-$74.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $40K | +$32.5K | +171 | New |
|
27
JP Morgan Chase
New York
| $33K | -$1.33K | -7 | -5% |
|
28
BNP Paribas Financial Markets
Paris,
France
| $29.4K | +$22.3K | +117 | +1,170% |
|
29
New York State Common Retirement Fund
Albany,
New York
| $24K | – | – | – |
|
30
Legal & General Group
London,
United Kingdom
| $20K | – | – | – |
|
|
SO
31
STRS Ohio
Columbus,
Ohio
| $19K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $16K | -$124K | -652 | -90% |
|
|
DOA
33
D'Orazio & Associates
Falls Church,
Virginia
| $15K | -$12.6K | -66 | -50% |
|
|
AIP
34
Ameritas Investment Partners
Lincoln,
Nebraska
| $12K | – | – | – |
|
35
Bank of Montreal
Toronto,
Ontario, Canada
| $5K | -$1.52K | -8 | -28% |
|
|
MAM
36
Meeder Asset Management
Dublin,
Ohio
| $4K | -$2.47K | -13 | -43% |
|
|
LTFS
37
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
DS
38
DRW Securities
Chicago,
Illinois
| – | -$108K | -763 | Closed |
|
|
OAM
39
Oxford Asset Management
Oxford,
United Kingdom
| – | -$91K | -648 | Closed |
|
CUE Hedge Fund Activity: Q1 2019 in Review
38 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2019, worth a combined $26.7M — up 76% from $15.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CUE positions and 2 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.03M. The largest seller was Morgan Stanley, cutting an estimated $175K.
- 38 institutional investors held Cue Biopharma (CUE) as of Q1 2019, up from 36 in Q4 2018.
- Funds reported $26.7M of Cue Biopharma stock for Q1 2019, up 76% quarter-over-quarter.
- 4 funds opened new Cue Biopharma positions in Q1 2019 and 2 closed out, a net change of +2 holders.
- The largest Cue Biopharma buyer in Q1 2019 was Vanguard Group, an estimated $1.03M added.
- The largest Cue Biopharma seller in Q1 2019 was Morgan Stanley, an estimated $175K sold.
Based on aggregated 13F filings for Q1 2019.